Glyburide and Enasidenib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Enasidenib
Glyburide
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased glyBURIDE exposure and an increased risk of glyBURIDE-related adverse effects
Interaction Deep Dive
Avoid coadministration of enasidenib and glyBURIDE. Enasidenib is an OATP1B1 inhibitor. Coadministration of enasidenib and glyBURIDE (OATP1B1 substrate with NTI) may increase the exposure of glyBURIDE, where minimal concentration changes may lead to serious toxicities. Coadministration of rosuvastatin (OATP1B1, OATP1B3, and BCRP substrate) with enasidenib increased rosuvastatin Cmax by 366% and AUC(0 to infinity) by 244%. If coadministration cannot be avoided, decrease the dosage of glyBURIDE as recommended and as clinically indicated1.
Why it happens (mechanism)
Inhibition of OATP1B1-efflux transport by enasidenib
Literature reports
1 report — tap to read
a) Coadministration of rosuvastatin 10 mg (OATP1B1, OATP1B3, and BCRP substrate) after multiple doses of enasidenib 100 mg (OATP1B1, OATP1B3, and BCRP inhibitor) increased rosuvastatin Cmax by 366% and AUC(0 to infinity) by 244% 1.
Common questions
Can I take Glyburide and Enasidenib together?
Increased glyBURIDE exposure and an increased risk of glyBURIDE-related adverse effects Always confirm with your pharmacist or prescriber before making any change.
How serious is the Glyburide and Enasidenib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Glyburide or Enasidenib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: IDHIFA(R) oral tablets, enasidenib oral tablets. Bristol-Myers Squibb (per FDA), Princeton, NJ, 2023. DailyMed
Keep reading about Enasidenib
Keep reading about Glyburide
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist